Congress has already adjourned for the year without taking action, but U.S. medical societies are hoping relief from significant Medicare cuts will arrive in early 2024. 

Revisit some of the year's biggest trends in the diagnosis, treatment and prevention of cardiovascular disease. 

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

AI-based prediction models have shown significant promise, but many are still flawed in a way that limits their value. 

Cardiovascular disease remains one of the leading causes of mortality in the world, responsible for nearly 20 million deaths in 2022 alone. 

Adolph M. Hutter, MD, spent more than 50 years with Massachusetts General Hospital and worked with multiple professional sports teams. In addition, he served as president of the American College of Cardiology in 1992-1993. 

The publication's current editor-in-chief is Valentin Fuster, MD, PhD. Harlan M. Krumholz, MD, will begin his five-year term in 2024.

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.